Schizophrenia

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.

Efficacy and safety of brilaroxazine for schizophrenia sustained for > 1 year in open-label extension of RECOVER, announced by Reviva Pharmaceuticals.

America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.

A study shows constipation has a causal relationship with schizophrenia and MDD, but the relationship with schizophrenia may have limited clinical implications.

Patients with schizophrenia and COVID-19 both present dysregulated energy metabolism, explaining the high COVID-19 rates among those with schizophrenia.

A study found patients with schizophrenia exhibiting violence, vs. those who don’t, have less gray matter volume in the frontal lobe and greater thyroid-stimulating hormone levels.

A new study supports mindfulness-based interventions as a complementary treatment for patients with schizophrenia spectrum disorders.

A study demonstrates many people with treatment-resistant schizophrenia do not comply with nutritional recommendations, which can contribute to increased mortality risk.

A study showed high-dose antipsychotics and benzodiazepines were linked to an increased mortality risk for those with schizophrenia. High-dose antidepressants lowered the risk.

A study identified homelessness and minority status as factors that impact clozapine prescription patterns.

A study found a 3.5-fold increased schizophrenia risk in those with hallucinogen-related emergency department visits.

Emraclidine fails to significantly reduce schizophrenia symptoms in phase 2 EMPOWER trials, with no statistical difference from placebo on PANSS score.

Phase 3 data shows lumateperone 42 mg significantly delayed relapse in patients with schizophrenia vs placebo, with 63% reduced relapse risk and good tolerance.

Teva presents 2 findings at Psych Congress 2024: TEV’749’s effects on social function and quality of life in adults with schizophrenia and risperidone adherence patterns.

This Month in Review captures top FDA news, phase 2b data, and early research in the psychiatry field.

EMERGENT-4 and EMERGENT-5, phase 3, 52-week trials, showed xanomeline trospium chloride significantly improved schizophrenia symptoms across 52 weeks.

Sexual trauma and genetic risk independently and together raise mental illness risk, a new study found.

A study found people with schizophrenia have a 4-fold higher risk of sudden cardiac death compared to the general population, underscoring the need for cardiometabolic care.

A new study identifies antipsychotics to avoid for patients with schizophrenia who have cognitive deficits, including haloperidol, fluphenazine, and clozapine.

Factors, including older age at onset and longer length of stay, may predict longevity for schizophrenia in psychiatric long-term care settings.

Second-generation long-acting injectables were particularly underutilized, and especially among older patients.

While this analysis found social anhedonia may be a potential intervention for some, nonsocial cognition may have a significant role in social disconnection for those with schizophrenia.

A short-term rise in air pollution levels between neighboring days was significantly linked to an increased risk of schizophrenia hospitalizations in China.

Findings suggest obstetric complications are associated with more severe psychopathological phenotypes in schizophrenia and related disorders.

A study of more than 130k with schizophrenia revealed significant variability in relapse and treatment failure rates across different antipsychotics.

Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.

These data suggest that relapse among those with schizophrenia may be common 6 months after ECT, with more than half of patients likely to experience relapse within 2 years.

Findings highlight high healthcare resource utilization and costs but low psychotherapy utilization, frequent relapse, and pharmacologic therapy discontinuation.

A study reveals that individuals with schizophrenia spectrum disorders experience high rates of comorbid mental health conditions and receive minimally adequate treatment.

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.